Drug intelligence / Profile preview

retlirafusp alfa + apatinib

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

Retlirafusp alfa + apatinib is an investigational combination therapy consisting of retlirafusp alfa (SHR-1701), a bifunctional fusion protein, and apatinib, a small-molecule tyrosine kinase inhibitor. Retlirafusp alfa is designed to simultaneously block the PD-1/PD-L1 and TGF-β signaling pathways by combining an anti-PD-L1 monoclonal antibody with the extracellular domain of the TGF-β receptor II (TGF-βRII). Apatinib is a selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), which inhibits tumor angiogenesis. This combination is being evaluated for its synergistic potential in treating advanced solid tumors, particularly hepatocellular carcinoma (HCC), by modulating the tumor microenvironment and enhancing anti-tumor immune responses.

Other names: SHR-1701 + rivoceranibSHR-1701 + apatinib mesylate

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)TGFB (GARP–latent transforming growth factor beta 1 complex)CD274 (Programmed cell death protein 1 ligand 1)SRC (Proto-oncogene tyrosine-protein kinase Src)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on retlirafusp alfa + apatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on retlirafusp alfa + apatinib.

Explore the full profile